MET and non-small cell lung carcinoma: A phase I trial of glesatinib in advanced, pre-treated, NSCLC patients with activating genetic MET alterations (mutation or amplification) has shown that the glesatinib safety profile was acceptable and the dosage of 750 mg twice daily (NCT00697632) [78] was selected for the subsequent phase II clinical trial (NCT02544633) evaluating glesatinib efficacy.